This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prolactinoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • prolactinoma is the most common form of pituitary tumour accounting for approximately 50% of pituitary adenomas
  • commonly diagnosed when raised prolactin levels are found during investigation of secondary amenorrhoea or galactorrhoea
  • alternative causes of raised prolactin levels includes pregnancy, hypothyroidism and drugs e.g. antipsychotics, anti-emetics
  • prolactinomas may occur as part of the MEN-1 syndrome
  • pituitary tumours are classified according to size - microadenomas (<1cm) and macroadenomas - prolactinomas are considered in terms of microprolactinomas and macroprolactinomas

Note that non-secretory pituitary adenomas may also cause hyperprolactinaemia - this may occur if a non-secretory adenoma disrupts the flow of hypothalmic dopamine (the physiological prolactin inhibitory factor) to the lactotrophs (the pituitary cells which produce prolactin).

  • giant prolactinomas, a rare subtype of macroadenomas, are characterized by large size (over 4 cm), very high prolactin levels (more than 1000 ng/ml) and invasive growth and are thus the most difficult to treat

Reference:

  • Melmed S, Casanueva FF, Hoffman AR, et al.Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96: 273-288.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.